OverviewSuggest Edit

Imago BioSciences is a clinical-stage biotechnology company developing treatments for myeloid diseases. It conducts research in bone marrow disease prevention and treatment, including acute myeloid leukemia, myelodysplastic syndrome, polycythemia vera, myelofibrosis, and essential thrombocythemia. The company focuses its research on an epigenetic enzyme, LSD1, for cancer therapy.
TypePublic
Founded2012
HQSouth San Francisco, CA, US
Websiteimagobio.com

Latest Updates

Employees (est.) (Jun 2021)17
Share Price (Nov 2021)$25(+5%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Imago BioSciences

Hugh Y. Rienhoff

Hugh Y. Rienhoff

Chief Executive Officer
Laura Eichorn

Laura Eichorn

Chief Operating Officer
Wan-Jen Hong

Wan-Jen Hong

Chief Medical Officer
Jennifer Peppe

Jennifer Peppe

Senior Vice President, Clinical Operations
Amy Tapper

Amy Tapper

Senior Vice President, Non-Clinical and CMC
Dennis Henner

Dennis Henner

Chairman
Show more

Imago BioSciences Office Locations

Imago BioSciences has an office in South San Francisco
South San Francisco, CA, US (HQ)
329 Oyster Point Blvd, 3rd Floor
Show all (1)

Imago BioSciences Financials and Metrics

Imago BioSciences Revenue

Market capitalization (12-Nov-2021)

799.7m

Closing stock price (12-Nov-2021)

25.0
Imago BioSciences's current market capitalization is $799.7 m.
USDQ2, 2021

Preferred Stock

44.9m
USDQ2, 2021

Net Income

(15.9m)

Depreciation and Amortization

4.0k

Accounts Payable

585.0k

Cash From Operating Activities

(14.2m)
Show all financial metrics

Imago BioSciences Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

Imago BioSciences Online and Social Media Presence

Embed Graph

Imago BioSciences Blogs

Imago BioSciences Appoints Laurie Keating to Board of Directors

Imago BioSciences Appoints Laurie Keating to Board of Directors Content Import Thu, 11/18/2021 - 16:08 Imago BioSciences Appoints Laurie Keating to Board of Directors November 18, 2021 This release is a backfill from a News Wire General …

Imago BioSciences Reports Third Quarter 2021 Financial Results and Provides Recent Business Updates

Imago BioSciences Reports Third Quarter 2021 Financial Results and Provides Recent Business Updates Content Import Wed, 11/10/2021 - 16:07 Imago BioSciences Reports Third Quarter 2021 Financial Results and Provides Recent Business Updates November 10, 2021 Th…

Imago BioSciences Announces Oral Data Presentations at the Upcoming 63rd American Society of Hematology Annual Meeting and Exposition

Imago BioSciences Announces Oral Data Presentations at the Upcoming 63rd American Society of Hematology Annual Meeting and Exposition Content Import Thu, 11/04/2021 - 16:13 Imago BioSciences Announces Oral Data Presentations at the Upcoming 63rd American Society of Hematology Annual Meetin…

Imago BioSciences Announces Its Addition to the Russell 2000® Index

Imago BioSciences Announces Its Addition to the Russell 2000® Index Content Import Mon, 09/20/2021 - 08:01 Imago BioSciences Announces Its Addition to the Russell 2000® Index September 20, 2021 This release is a backfill from a News Wire Genera…

Imago BioSciences Reports Second Quarter 2021 Financial Results and Provides Recent Business Updates

Imago BioSciences Reports Second Quarter 2021 Financial Results and Provides Recent Business Updates Content Import Thu, 08/19/2021 - 16:01 Imago BioSciences Reports Second Quarter 2021 Financial Results and Provides Recent Business Updates August 19, 2021 Th…

Imago BioSciences Receives Orphan Designation From European Medicines Agency for Bomedemstat for the Treatment of Essential Thrombocythemia

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 30, 2021-- Imago BioSciences, Inc. (Imago) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that the European Medicines Agency (EMA) has
Show more

Imago BioSciences Frequently Asked Questions

  • When was Imago BioSciences founded?

    Imago BioSciences was founded in 2012.

  • Who are Imago BioSciences key executives?

    Imago BioSciences's key executives are Hugh Y. Rienhoff, Laura Eichorn and Wan-Jen Hong.

  • How many employees does Imago BioSciences have?

    Imago BioSciences has 17 employees.

  • Who are Imago BioSciences competitors?

    Competitors of Imago BioSciences include Bristol-Myers Squibb, Merck and Incyte.

  • Where is Imago BioSciences headquarters?

    Imago BioSciences headquarters is located at 329 Oyster Point Blvd, 3rd Floor, South San Francisco.

  • Where are Imago BioSciences offices?

    Imago BioSciences has an office in South San Francisco.

  • How many offices does Imago BioSciences have?

    Imago BioSciences has 1 office.